XML 20 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Statements of Cash Flows Statement (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Cash flows from operating activities:    
Net Loss, Including Portion Attributable to Noncontrolling Interest $ (50,521) $ (23,853)
Adjustments to reconcile net loss including noncontrolling interests in operating subsidiaries to net cash provided by (used in) operating activities:    
Depreciation and amortization 43,753 37,085
Non-cash stock compensation 14,022 20,812
Excess tax benefits from stock-based compensation 0 (358)
Other (24) (22)
Changes in assets and liabilities:    
Accounts receivable (6,361) (6,969)
Prepaid expenses and other assets 1,719 (5,866)
Accounts payable and accrued expenses / costs 5,503 6,874
Royalties and contingent legal fees payable 7,330 (4,195)
Deferred income tax (1,531) (29,043)
Net cash provided by (used in) operating activities 13,890 (4,819)
Cash flows from investing activities:    
Purchases of property and equipment (106) (579)
Purchase of available-for-sale investments (76,130) (232,809)
Maturities and sale of available-for-sale investments 133,878 155,669
Investments in patents/ patent rights (24,518) (10,416)
Net cash provided by (used in) investing activities 33,124 (88,135)
Cash flows from financing activities:    
Distributions to noncontrolling interests in operating subsidiary 867 0
Payments of Dividends (18,773) (12,392)
Contributions from noncontrolling interests in operating subsidiary 0 1,920
Payments for Repurchase of Common Stock 0 18
Excess tax benefits from stock-based compensation 0 (358)
Proceeds from exercises of stock options 198 301
Net cash used in financing activities (19,442) (10,547)
Increase (decrease) in cash and cash equivalents 27,572 (103,501)
Cash and cash equivalents, beginning 126,685 221,804
Cash and cash equivalents, ending 154,257 118,303
Patent acquisition costs included in accrued expenses $ 2,000 $ 9,750